Novel transplant of combined platelet-rich fibrin Releasate and bone marrow stem cells prevent bone loss in Ovariectomized osteoporotic mice.
Bone marrow
Osteoporosis
Platelet-rich fibrin
Releasates
Stem cell
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
08 Aug 2020
08 Aug 2020
Historique:
received:
08
05
2020
accepted:
30
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Osteoporosis is a metabolic bone disorder characterized by deterioration in the quantity and quality of bone tissue, with a consequent increase susceptibility to fracture. In this study, we sought to determine the efficacy of platelet-rich fibrin releasates (PRFr) in augmenting the therapeutic effects of stem cell-based therapy in treating osteoporotic bone disorder. An osteoporosis mouse model was established through bilateral ovariectomy on 12-week-old female ICR (Institute of Cancer Research) mice. Eight weeks postoperatively, the ovariectomized (OVX) mice were left untreated (control) or injected with PRFr, bone marrow stem cells (BMSCs), or the combination of BMSCs and PRFr. Two different injection (single versus quadruple) dosages were tested to investigate the accumulative effects of BMSCS and PRFr on bone quality. Eight weeks after injection, the changes in tibial microstructural profiles included the percentage of bone volume versus total tissue volume (BV/TV, %), bone mineral density (BMD, g/cm3), trabecular number (Tb.N, number/mm), and trabecular separation (Tb.Sp, mm) and bony histology were analyzed. Postmenopausal osteoporosis model was successfully established in OVX mice, evidenced by reduced BMD, decreased BV/TV, lower Tb.N but increased Tb.Sp. Eight weeks after injection, there was no significant change to BMD and bone trabeculae could be detected in mice that received single-injection regimen. In contrast, in mice which received 4 doses of combined PRFr and BMSCs, the BMD, BV/TV, and TB.N increased, and the TB.Sp decreased significantly compared to untreated OVX mice. Moreover, the histological analysis showed the trabecular spacing become narrower in OVX-mice treated with quadruple injection of BMSCs and combined PRFr and BMSCs than untreated control. The systemic administration of combined BMSCs and PRFr protected against OVX-induced bone mass loss in mice. Moreover, the improvement of bony profile scores in quadruple-injection group is better than the single-injection group, probably through the increase in effect size of cells and growth factors. Our data also revealed the combination therapy of BMSCs and PRFr has better effect in enhancing osteogenesis, which may provide insight for the development of a novel therapeutic strategy in osteoporosis treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoporosis is a metabolic bone disorder characterized by deterioration in the quantity and quality of bone tissue, with a consequent increase susceptibility to fracture.
METHODS
METHODS
In this study, we sought to determine the efficacy of platelet-rich fibrin releasates (PRFr) in augmenting the therapeutic effects of stem cell-based therapy in treating osteoporotic bone disorder. An osteoporosis mouse model was established through bilateral ovariectomy on 12-week-old female ICR (Institute of Cancer Research) mice. Eight weeks postoperatively, the ovariectomized (OVX) mice were left untreated (control) or injected with PRFr, bone marrow stem cells (BMSCs), or the combination of BMSCs and PRFr. Two different injection (single versus quadruple) dosages were tested to investigate the accumulative effects of BMSCS and PRFr on bone quality. Eight weeks after injection, the changes in tibial microstructural profiles included the percentage of bone volume versus total tissue volume (BV/TV, %), bone mineral density (BMD, g/cm3), trabecular number (Tb.N, number/mm), and trabecular separation (Tb.Sp, mm) and bony histology were analyzed.
RESULTS
RESULTS
Postmenopausal osteoporosis model was successfully established in OVX mice, evidenced by reduced BMD, decreased BV/TV, lower Tb.N but increased Tb.Sp. Eight weeks after injection, there was no significant change to BMD and bone trabeculae could be detected in mice that received single-injection regimen. In contrast, in mice which received 4 doses of combined PRFr and BMSCs, the BMD, BV/TV, and TB.N increased, and the TB.Sp decreased significantly compared to untreated OVX mice. Moreover, the histological analysis showed the trabecular spacing become narrower in OVX-mice treated with quadruple injection of BMSCs and combined PRFr and BMSCs than untreated control.
CONCLUSION
CONCLUSIONS
The systemic administration of combined BMSCs and PRFr protected against OVX-induced bone mass loss in mice. Moreover, the improvement of bony profile scores in quadruple-injection group is better than the single-injection group, probably through the increase in effect size of cells and growth factors. Our data also revealed the combination therapy of BMSCs and PRFr has better effect in enhancing osteogenesis, which may provide insight for the development of a novel therapeutic strategy in osteoporosis treatment.
Identifiants
pubmed: 32770974
doi: 10.1186/s12891-020-03549-y
pii: 10.1186/s12891-020-03549-y
pmc: PMC7415181
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
527Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : 103-2313-B-002-040-MY2
Organisme : Taipei Medical University
ID : TMU108-AE1-B03
Références
Ageing Res Rev. 2006 Feb;5(1):91-116
pubmed: 16310414
Maturitas. 2014 Jul;78(3):199-204
pubmed: 24842796
Curr Osteoporos Rep. 2014 Mar;12(1):41-7
pubmed: 24407712
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e37-44
pubmed: 16504849
Korean J Lab Med. 2011 Jul;31(3):212-8
pubmed: 21779198
Int J Mol Sci. 2020 Jan 16;21(2):
pubmed: 31963217
J Clin Invest. 2005 Dec;115(12):3318-25
pubmed: 16322775
Orthopedics. 2009 Dec;32(12):900
pubmed: 20000241
J Periodontol. 2007 Oct;78(10):1985-91
pubmed: 18062120
N Engl J Med. 2006 May 25;354(21):2250-61
pubmed: 16723616
Rheumatology (Oxford). 2014 Oct;53(10):1911-3
pubmed: 25099769
Expert Opin Biol Ther. 2017 Feb;17(2):255-263
pubmed: 28064540
Science. 2000 Sep 1;289(5484):1508-14
pubmed: 10968781
P T. 2018 Feb;43(2):92-104
pubmed: 29386866
Arthroscopy. 2019 May;35(5):1486-1497
pubmed: 30979627
Connect Tissue Res. 2014 Aug;55(4):304-9
pubmed: 24874552
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e56-60
pubmed: 16504852
Acta Cir Bras. 2017 Sep;32(9):767-780
pubmed: 29019594
Biologicals. 2012 Sep;40(5):323-9
pubmed: 22841724
Life Sci. 2016 May 1;152:244-8
pubmed: 26596563
Tissue Eng Part A. 2011 Feb;17(3-4):349-59
pubmed: 20799908
Tissue Eng Part C Methods. 2016 Jan;22(1):49-58
pubmed: 26467221
Dev Cell. 2002 Apr;2(4):389-406
pubmed: 11970890
Bull Exp Biol Med. 2014 Feb;156(4):560-5
pubmed: 24771449
J Orthop Trauma. 2008 Oct;22(9):595-604
pubmed: 18827588
Biomaterials. 2011 Oct;32(28):6773-80
pubmed: 21700330
Clin Geriatr Med. 2014 May;30(2):317-32
pubmed: 24721371
Cell Stem Cell. 2010 Nov 5;7(5):553-4
pubmed: 21040895
Am J Med. 2013 Jan;126(1):13-20
pubmed: 23177553
Lancet. 2019 Jan 26;393(10169):364-376
pubmed: 30696576
Int J Mol Sci. 2017 Aug 07;18(8):
pubmed: 28783120
J Bone Miner Metab. 2008;26(1):1-8
pubmed: 18095057
PLoS Genet. 2010 Jul 08;6(7):e1001019
pubmed: 20628571
Am J Sports Med. 2009 Nov;37(11):2259-72
pubmed: 19875361
Inflamm Allergy Drug Targets. 2010 Dec;9(5):393-9
pubmed: 20518723
Nat Med. 2007 Dec;13(12):1496-503
pubmed: 18059282
Bone. 2000 May;26(5):485-9
pubmed: 10773588
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jul;108(1):56-61
pubmed: 19451002
J Orthop Res. 2001 Jan;19(1):117-25
pubmed: 11332607
Am J Sports Med. 2017 Nov;45(13):3128-3142
pubmed: 28892654
Stem Cells Int. 2016;2016:9458396
pubmed: 27994625
Med Sci Monit. 2016 Jan 21;22:226-33
pubmed: 26795027
Biomaterials. 2012 Dec;33(34):8802-11
pubmed: 22981779